First Tarantino NFT sold for $1m
Raffaele Redi •
NKTR
NKTR
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain based on its PEGylation and polymer conjugate technology platforms in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology. It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia. In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis. Further, it is developing SEMPRANA to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreements with AstraZeneca AB, Shire plc, Pfizer Inc., Amgen Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, and Bristol-Myers Squibb Company. The company was founded in 1990 and is headquartered in San Francisco, California.
White Paper Declaration
White Paper Declaration
1BTC
Invest
20BTC
Profit
Leverage:
x20
The Power Of Leverage
Trade in the big leagues with 100 Bitcoin for every 1 Bitcoin you put in
NKTR price history
| Date | Close | Change | Change(%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 21, 2022 | 10.89 | -0.66 | -5.71% | 11.55 | 11.81 | 10.85 |
| Jan 20, 2022 | 11.72 | -0.49 | -4.01% | 12.21 | 12.52 | 11.71 |
| Jan 19, 2022 | 12.08 | 0.34 | 2.90% | 11.74 | 12.25 | 11.63 |
| Jan 18, 2022 | 11.67 | -0.26 | -2.18% | 11.93 | 12.18 | 11.35 |
| Jan 14, 2022 | 12.04 | 0.27 | 2.29% | 11.77 | 12.08 | 11.48 |
| Jan 13, 2022 | 11.95 | -0.22 | -1.81% | 12.17 | 12.38 | 11.78 |
| Jan 12, 2022 | 12.22 | -0.05 | -0.41% | 12.27 | 12.34 | 11.78 |
| Jan 11, 2022 | 12.29 | -0.04 | -0.32% | 12.33 | 12.69 | 12.25 |
| Jan 10, 2022 | 12.48 | -0.07 | -0.56% | 12.55 | 12.60 | 12.19 |
| Jan 7, 2022 | 12.60 | 0.07 | 0.56% | 12.53 | 13.21 | 12.52 |
| Jan 6, 2022 | 12.63 | 0.37 | 3.02% | 12.26 | 12.71 | 11.96 |
| Jan 5, 2022 | 12.68 | -0.67 | -5.02% | 13.35 | 13.76 | 12.48 |
| Jan 4, 2022 | 13.64 | 0.20 | 1.49% | 13.44 | 13.74 | 13.22 |
| Jan 3, 2022 | 13.58 | 0.10 | 0.74% | 13.48 | 13.99 | 13.32 |
| Dec 31, 2021 | 13.44 | -0.24 | -1.75% | 13.68 | 14.25 | 13.41 |
| Dec 30, 2021 | 13.94 | 0.00 | 0.00% | 13.94 | 14.53 | 13.85 |
| Dec 29, 2021 | 14.14 | -0.58 | -3.94% | 14.72 | 14.84 | 14.10 |
| Dec 28, 2021 | 14.96 | -0.11 | -0.73% | 15.07 | 15.35 | 14.84 |
| Dec 27, 2021 | 15.30 | -0.26 | -1.67% | 15.56 | 15.64 | 15.04 |
| Dec 23, 2021 | 15.60 | 0.15 | 0.97% | 15.45 | 15.87 | 15.42 |